Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500

Scotiabank analyst Louise Chen has reaffirmed a Sector Outperform rating on Amgen (NASDAQ: AMGN) and increased the price target from $450 to $500. This adjustment reflects a positive outlook on the company's performance in the sector.